Regarding the genetically proxied TG-lowering inhibition, ANGPTL3 variants were associated with lower risk of aortic aneurysms (OR = 0.51, 95% CI = 0.29–0.89, p = 0.02) and cerebral aneurysms in the UK Biobank cohort (OR = 0.12, 95% CI = 0.02–0.62, p = 0.012). This evidence concerns the gene ANGPTL3 and aortic aneurysm.